Popular Stories
Avise Analytics | NYSE
426
archive,tag,tag-nyse,tag-426,ajax_fade,page_not_loaded,,side_area_uncovered_from_content,qode-child-theme-ver-1.0.0,qode-theme-ver-7.4,wpb-js-composer js-comp-ver-5.0.1,vc_responsive

NYSE Tag

  • All
  • Biotechnology
  • Cannabis
  • Investing Ideas
  • Macro
  • Miscellaneous
  • Sectors
  • Startups
  • Technologies
  • Trending
  • Uncategorized
Can Cara Therapeutics buck the trend?

Cara Therapeutics (NASDAQ: CARA) recently posted its first quarter, 2019 results. The company reported a net loss of $22.0 million, or $0.56 per basic and diluted share compared to a net loss of $16.8 million, or $0.51 per basic and diluted share, for the first...

G1 Therapeutics stock soars on news of NDA for Triaciclib

G1 Therapeutics (NASDAQ: GTHX) shares soared by almost 25% on the basis of news that it had a productive phase 2 meeting with the FDA for the company’s lead candidate Trilaciclib, a first-in-class myelopreservation agent that protects the bone marrow from damage by chemotherapy. The...

Emerging Therapeutics in Preeclampsia Management

Preeclampsia is a pregnancy related complication that affects over 5% to 8% of pregnancies or about 3,00,000 women in the US alone. An estimated 10,500 babies in the U.S, succumb to preeclampsia while others suffer from extensive damage owing to premature delivery. It is one of...

WordPress Video Lightbox Plugin